Brokerages expect HEXO Corp. (NASDAQ:HEXO) to announce $19.66 million in sales for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for HEXO’s earnings, with estimates ranging from $18.04 million to $20.77 million. The firm is expected to issue its next quarterly earnings report on Thursday, September 12th.

According to Zacks, analysts expect that HEXO will report full year sales of $45.07 million for the current financial year, with estimates ranging from $43.50 million to $47.93 million. For the next financial year, analysts forecast that the business will report sales of $260.94 million, with estimates ranging from $138.58 million to $338.18 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover HEXO.

HEXO (NASDAQ:HEXO) last released its earnings results on Thursday, June 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.01. The business had revenue of $11.98 million for the quarter, compared to analyst estimates of $10.96 million.

A number of equities research analysts have issued reports on the stock. Oppenheimer set a $14.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a report on Tuesday, June 25th. AltaCorp Capital reiterated an “outperform” rating on shares of HEXO in a report on Thursday, April 4th. Zacks Investment Research upgraded shares of HAYS PLC/ADR from a “sell” rating to a “hold” rating in a report on Tuesday, June 18th. CIBC reiterated a “market perform” rating on shares of HEXO in a report on Tuesday, June 25th. Finally, Desjardins reiterated a “buy” rating on shares of Horizons Enhcd Inc Eqy Cl E Unt Etf in a report on Thursday, April 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $8.63.

Several large investors have recently made changes to their positions in HEXO. FIL Ltd purchased a new stake in shares of HEXO in the 1st quarter valued at approximately $4,691,000. Bank of Montreal Can purchased a new stake in shares of HEXO in the 1st quarter valued at approximately $3,439,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp purchased a new stake in shares of HEXO in the 1st quarter valued at approximately $2,949,000. CIBC World Markets Inc. purchased a new stake in shares of HEXO in the 1st quarter valued at approximately $1,676,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of HEXO in the 1st quarter valued at approximately $1,572,000.

HEXO stock traded down $0.30 during mid-day trading on Monday, reaching $4.85. 5,814,845 shares of the company’s stock were exchanged, compared to its average volume of 3,492,660. HEXO has a twelve month low of $3.02 and a twelve month high of $8.40. The stock’s fifty day simple moving average is $5.84.

HEXO Company Profile

HEXO Corp., through its subsidiary, HEXO Operations Inc, produces, markets, and sells cannabis in Canada. The company offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. It provides its products under the HEXO and Hydropothecary brand names.

Featured Article: What Does Beta Mean In Stock Selection

Get a free copy of the Zacks research report on HEXO (HEXO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for HEXO (NASDAQ:HEXO)

Receive News & Ratings for HEXO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HEXO and related companies with MarketBeat.com's FREE daily email newsletter.